Booth Bruce 4
4 · Kymera Therapeutics, Inc. · Filed Jun 30, 2026
Research Summary
AI-generated summary of this filing
Kymera Therapeutics (KYMR) Director Bruce Booth Sells 513K Shares
What Happened
- Bruce Booth, a director of Kymera Therapeutics (KYMR), reported multiple open-market sales totaling 513,245 shares for aggregate proceeds of approximately $56.46 million. The sales occurred on June 26 and June 29, 2026, at prices reported (weighted averages and individual trades) roughly between $105.02 and $119.04 per share.
- These transactions are reported as sales (code S). Many of the shares sold were held by Atlas Venture–affiliated vehicles (see footnotes) and at least some sales were made pursuant to a Rule 10b5-1 trading plan adopted on December 11, 2025.
Key Details
- Transaction dates: June 26, 2026 and June 29, 2026. Prices per trade ranged (weighted averages reported) roughly $105.02–$119.04; total proceeds ≈ $56.46M for 513,245 shares.
- Ownership after the transactions: not specified in the excerpt provided — check the full Form 4 filing(s) for post-transaction holdings. Several lines disclose the shares are held directly by Atlas Venture funds and the reporting person disclaims Section 16 beneficial ownership except to the extent of any pecuniary interest (see footnote F15/F3).
- Notable footnotes: F1 indicates a Rule 10b5-1 plan adopted by Atlas Venture funds on 12/11/2025; multiple footnotes note weighted-average prices and price ranges across multiple trades (see filing). The report is split across two filings due to the 30-line Table I limitation; this is the first of two.
- Timeliness: Form 4 was filed on June 30, 2026. Given the trade dates (June 26 and June 29), this filing appears to have been made within the standard two-business-day reporting window.
Context
- These are sales (often routine for funds or prearranged plans) rather than purchases; sales do not necessarily indicate management view on company fundamentals. Because many shares were held and sold by Atlas Venture funds (institutional vehicles) and Booth disclaims beneficial ownership of those fund holdings (except for any pecuniary interest), these trades reflect affiliated fund activity as well as the reporting person’s role in those entities.
- Several reported prices are weighted averages covering multiple executions; consult the full Form 4 and footnotes for detailed per-trade price breakdowns and to confirm exact holdings after the sales.
Insider Transaction Report
Form 4
Booth Bruce
Director
Transactions
- Sale
Common Stock
[F1][F2][F3]2026-06-26$107.57/sh−28,296$3,043,801→ 2,834,055 total(indirect: See footnote) - Sale
Common Stock
[F1][F4][F3]2026-06-26$108.14/sh−231,007$24,981,097→ 2,603,048 total(indirect: See footnote) - Sale
Common Stock
[F1][F5][F3]2026-06-26$109.79/sh−32,624$3,581,789→ 2,570,424 total(indirect: See footnote) - Sale
Common Stock
[F1][F6][F3]2026-06-26$110.49/sh−11,277$1,245,996→ 2,559,147 total(indirect: See footnote) - Sale
Common Stock
[F1][F7][F3]2026-06-26$111.51/sh−10,366$1,155,913→ 2,548,781 total(indirect: See footnote) - Sale
Common Stock
[F1][F8][F3]2026-06-26$112.49/sh−555$62,432→ 2,548,226 total(indirect: See footnote) - Sale
Common Stock
[F1][F9][F3]2026-06-26$113.97/sh−14,913$1,699,635→ 2,533,313 total(indirect: See footnote) - Sale
Common Stock
[F1][F10][F3]2026-06-26$114.94/sh−27,951$3,212,688→ 2,505,362 total(indirect: See footnote) - Sale
Common Stock
[F1][F11][F3]2026-06-26$115.69/sh−6,821$789,121→ 2,498,541 total(indirect: See footnote) - Sale
Common Stock
[F1][F12][F3]2026-06-26$117.09/sh−12,181$1,426,273→ 2,486,360 total(indirect: See footnote) - Sale
Common Stock
[F1][F13][F3]2026-06-26$117.85/sh−22,046$2,598,121→ 2,464,314 total(indirect: See footnote) - Sale
Common Stock
[F1][F14][F3]2026-06-26$118.66/sh−12,390$1,470,197→ 2,451,924 total(indirect: See footnote) - Sale
Common Stock
[F1][F2][F15]2026-06-26$107.57/sh−3,958$425,762→ 525,760 total(indirect: See footnote) - Sale
Common Stock
[F1][F4][F15]2026-06-26$108.14/sh−32,402$3,503,952→ 493,358 total(indirect: See footnote) - Sale
Common Stock
[F1][F5][F15]2026-06-26$109.79/sh−4,562$500,862→ 488,796 total(indirect: See footnote) - Sale
Common Stock
[F1][F6][F15]2026-06-26$110.49/sh−1,579$174,464→ 487,217 total(indirect: See footnote) - Sale
Common Stock
[F1][F7][F15]2026-06-26$111.51/sh−1,442$160,797→ 485,775 total(indirect: See footnote) - Sale
Common Stock
[F1][F8][F15]2026-06-26$112.49/sh−78$8,774→ 485,697 total(indirect: See footnote) - Sale
Common Stock
[F1][F9][F15]2026-06-26$113.97/sh−2,083$237,400→ 483,614 total(indirect: See footnote) - Sale
Common Stock
[F1][F10][F15]2026-06-26$114.94/sh−3,896$447,806→ 479,718 total(indirect: See footnote) - Sale
Common Stock
[F1][F11][F15]2026-06-26$115.69/sh−952$110,137→ 478,766 total(indirect: See footnote) - Sale
Common Stock
[F1][F12][F15]2026-06-26$117.09/sh−1,701$199,170→ 477,065 total(indirect: See footnote) - Sale
Common Stock
[F1][F13][F15]2026-06-26$117.85/sh−3,069$361,682→ 473,996 total(indirect: See footnote) - Sale
Common Stock
[F1][F14][F15]2026-06-26$118.66/sh−1,729$205,163→ 472,267 total(indirect: See footnote) - Sale
Common Stock
[F1][F16][F3]2026-06-29$105.78/sh−5,471$578,722→ 2,446,453 total(indirect: See footnote) - Sale
Common Stock
[F1][F17][F3]2026-06-29$106.63/sh−14,613$1,558,184→ 2,431,840 total(indirect: See footnote) - Sale
Common Stock
[F1][F18][F3]2026-06-29$107.76/sh−19,093$2,057,462→ 2,412,747 total(indirect: See footnote) - Sale
Common Stock
[F1][F16][F15]2026-06-29$105.78/sh−848$89,701→ 471,419 total(indirect: See footnote) - Sale
Common Stock
[F1][F17][F15]2026-06-29$106.63/sh−2,318$247,168→ 469,101 total(indirect: See footnote) - Sale
Common Stock
[F1][F18][F15]2026-06-29$107.76/sh−3,024$325,866→ 466,077 total(indirect: See footnote)
Footnotes (18)
- [F1]This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025.
- [F10]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.2766 to $115.2672 inclusive.
- [F11]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.27 to $116.2626 inclusive.
- [F12]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.2731 to $117.2668 inclusive.
- [F13]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.2728 to $118.2599 inclusive.
- [F14]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $118.2717 to $119.035 inclusive.
- [F15]The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any.
- [F16]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.015 to $106.0145 inclusive.
- [F17]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.0271 to $106.96 inclusive.
- [F18]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.03 to $108.0293 inclusive.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.995 to $107.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the ranges set forth in footnotes (2), (4) through (14), and (16) through (18).
- [F3]These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.00 to 108.9725 inclusive.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.02 to $110.0166 inclusive.
- [F6]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.02 to $111.0075 inclusive.
- [F7]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.1057 to $111.9188 inclusive.
- [F8]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.1843 to $113.0139 inclusive.
- [F9]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.2614 to $114.246 inclusive.
Signature
/s/ Ommer Chohan, Attorney-in-Fact|2026-06-30